Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 19;376:e066084. doi: 10.1136/bmj-2021-066084

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig 3 — Estimation of relative treatment effects on remission (above diagonal line) and dropout (below diagonal line). Results are risk ratios (95% confidence intervals) between each pair of treatments from network meta-analysis. Comparisons are read from right to left. For example, the risk ratio for remission with tricyclic antidepressants (TCAs) compared with benzodiazepines (BZDs) is 0.94 (0.85 to 1.05). For dropout, the effect of TCAs compared with BZDs on the risk of dropout is 1.54 (1.19 to 1.99). Bold font indicates statistical significance. GRADE certainty of evidence of each comparison is: light green=moderate; light red=low; dark red=very low. MAOI=monoamine oxidase inhibitor; NaSSA=noradrenergic and specific serotonergic antidepressant; NRI=noradrenaline reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor; SNRI=serotonin-noradrenaline reuptake inhibitor